# Starling Oncology, Inc.: overview STLN · Nasdaq · CIK 1799191 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/stln.md) · [Financials](/companies/stln/financials.md) · [Filings](/companies/stln/filings.md) · [Insiders](/companies/stln/insiders.md) Latest reported revenue: [$161.3m](/filings/0001799191-26-000017.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001799191-26-000017). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [99.9](/filings/0001799191-25-000036.md) | [100 d](/filings/0001799191-26-000007.md) | [104](/filings/0001799191-26-000010.md) | [120](/filings/0001799191-26-000017.md) | [137](/filings/0001799191-25-000036.md) | [142 d](/filings/0001799191-26-000007.md) | [147](/filings/0001799191-26-000010.md) | [161](/filings/0001799191-26-000017.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(13.9%)](/filings/0001799191-25-000036.md) | [(11.9%) d](/filings/0001799191-26-000007.md) | [(9.5%)](/filings/0001799191-26-000010.md) | [(9.4%)](/filings/0001799191-26-000017.md) | [(5.9%)](/filings/0001799191-25-000036.md) | [(4.9%) d](/filings/0001799191-26-000007.md) | [(4.4%)](/filings/0001799191-26-000010.md) | [(2.9%)](/filings/0001799191-26-000017.md) | | Net margin | % | [(16.1%)](/filings/0001799191-25-000036.md) | [(13.1%) d](/filings/0001799191-26-000007.md) | [(18.8%)](/filings/0001799191-26-000017.md) | [(14.2%)](/filings/0001799191-26-000017.md) | [(12.1%)](/filings/0001799191-25-000036.md) | [(5.3%) d](/filings/0001799191-26-000007.md) | [(1.7%)](/filings/0001799191-26-000017.md) | [(6.1%)](/filings/0001799191-26-000017.md) | | Diluted EPS | $ per share | [(0.18)](/filings/0001799191-25-000036.md) | not reported | [(0.21)](/filings/0001799191-26-000010.md) | [(0.15)](/filings/0001799191-26-000017.md) | [(0.14)](/filings/0001799191-25-000036.md) | not reported | [(0.02)](/filings/0001799191-26-000010.md) | [(0.08)](/filings/0001799191-26-000017.md) | | Free cash flow | $m | [0.4 d](/filings/0001799191-25-000036.md) | [2.2 d](/filings/0001799191-25-000014.md) | [(5.3)](/filings/0001799191-26-000010.md) | [(11.4) d](/filings/0001799191-26-000017.md) | [(13.2) d](/filings/0001799191-25-000036.md) | [2.2 d](/filings/0001799191-26-000007.md) | [(3.3)](/filings/0001799191-26-000010.md) | [11.0 d](/filings/0001799191-26-000017.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [203](/filings/0001628280-23-008315.md) | [252](/filings/0001628280-24-013444.md) | [324](/filings/0001799191-25-000014.md) | [393](/filings/0001799191-26-000007.md) | [503](/filings/0001799191-26-000007.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(22.6%)](/filings/0001628280-23-008315.md) | [(32.5%)](/filings/0001628280-24-013444.md) | [(23.8%)](/filings/0001799191-25-000014.md) | [(15.3%)](/filings/0001799191-26-000007.md) | [(7.2%)](/filings/0001799191-26-000007.md) | | Net margin | % | [(5.4%)](/filings/0001628280-23-008315.md) | [0.1%](/filings/0001628280-24-013444.md) | [(25.6%)](/filings/0001799191-25-000014.md) | [(16.4%)](/filings/0001799191-26-000007.md) | [(12.1%)](/filings/0001799191-26-000007.md) | | Diluted EPS | $ per share | [(0.16)](/filings/0001628280-23-008315.md) | [(0.21)](/filings/0001628280-24-013444.md) | [(0.92)](/filings/0001799191-25-000014.md) | [(0.71)](/filings/0001799191-26-000007.md) | [(0.54)](/filings/0001799191-26-000007.md) | | Free cash flow | $m | [(35.5)](/filings/0001628280-23-008315.md) | [(67.3)](/filings/0001628280-24-013444.md) | [(40.9)](/filings/0001799191-25-000014.md) | [(30.3)](/filings/0001799191-26-000007.md) | [(27.8)](/filings/0001799191-26-000007.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/stln/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $25.8m | 4,749,030 | | Added +333,163 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $18.2m | 3,360,052 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $17.7m | 3,265,531 | | Reduced −211,250 | | [JOSH ARNOLD INVESTMENT CONSULTANT, LLC](/funds/1911348.md) | 2026-06-30 | $13.4m | 2,464,359 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $10.3m | 1,899,998 | | Added +142,151 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $9.4m | 1,735,337 | | Added +383,438 | | [WEXFORD CAPITAL LP](/funds/1048462.md) | 2026-06-30 | $9.3m | 1,711,323 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $8.4m | 1,552,917 | | Added +91,463 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $8.3m | 1,520,100 | Call | Added +1,001,200 | | [Nuveen, LLC](/funds/1871926.md) | 2026-06-30 | $7.6m | 1,408,720 | | Added +1,313,456 | ## Recent filings [All 543 filings](/companies/stln/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-02 | 20:41 ET | [8-K](/filings/0001079973-26-001208.md) | 5.02 Departure or appointment of officers or directors | 0001079973-26-001208 | | 2026-08-21 | 17:25 ET | [8-K](/filings/0001079973-26-001169.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001079973-26-001169 | | 2026-08-06 | 16:36 ET | [10-Q](/filings/0001799191-26-000017.md) | Quarterly report, period 2026-06-30 | 0001799191-26-000017 | | 2026-08-06 | 16:32 ET | [8-K](/filings/0001079973-26-001006.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001079973-26-001006 | | 2026-08-03 | 09:00 ET | [8-K](/filings/0001079973-26-000997.md) | 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001079973-26-000997 | | 2026-07-07 | 17:00 ET | [8-K](/filings/0001079973-26-000934.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001079973-26-000934 | | 2026-06-18 | 16:30 ET | [8-K](/filings/0001553350-26-000093.md) | 5.07 Shareholder vote results | 0001553350-26-000093 | | 2026-05-22 | 16:30 ET | [8-K](/filings/0001079973-26-000721.md) | 1.05 Material cybersecurity incident; 9.01 Financial statements and exhibits | 0001079973-26-000721 | | 2026-05-15 | 16:30 ET | [SCHEDULE 13D/A](/filings/0001213900-26-057832.md) | Ownership report, active investor, amended | 0001213900-26-057832 | | 2026-05-07 | 16:12 ET | [8-K](/filings/0001079973-26-000611.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001079973-26-000611 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001799191-26-000007.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9df89b06-6691-4b60-8602-6d84233a883f) ## About the filer - CIK: 1799191 - Tickers: STLN, DFPH, STLNW - Exchange: Nasdaq - SIC code: 8011 Services-Offices & Clinics of Doctors of Medicine - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.